Free press releases distribution network?

Agency / Source: LifeSensors, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



LifeSensors Awarded U.S. Patent for Novel Ubiquitin Pathway Enzyme Substrates - LifeSensors, Inc., has been awarded a U.S. patent for the development of novel, fluorescent di- and poly-ubiquitin deubiquitinase (DUB) substrates (US 8,518,660) - LifeSensors.com
LifeSensors Awarded U.S. Patent for Novel Ubiquitin Pathway Enzyme Substrates

 

PRZOOM - /newswire/ - Malvern, PA, United States, 2013/09/12 - LifeSensors, Inc., has been awarded a U.S. patent for the development of novel, fluorescent di- and poly-ubiquitin deubiquitinase (DUB) substrates (US 8,518,660) - LifeSensors.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

LifeSensors, Inc., a biotech company developing cutting-edge technologies for studying the ubiquitin pathway, has been awarded a U.S. patent for the development of novel, fluorescent di- and poly-ubiquitin deubiquitinase (DUB) substrates (US 8,518, 660). DUBs, which remove ubiquitin from human proteins, are important targets for drug discovery in a number of therapeutic areas and optimal DUB substrates are essential for these efforts.

Utilizing internally quenched fluorescence (IQF) technology, the patented substrates provide for the sensitive detection of deubiquitinating enzyme activity on ubiquitin chains with specific lysine linkages. Other available deubiquitinase substrates measure cleavage of linear peptide or amide bonds. The IQF- polyubiquitins, however, are conjugated via true isopeptide bonds and serve as more physiologically relevant enzyme targets. “These IQF-DiUb™ substrates create opportunities for improved measurement of physiologically relevant deubiquitylase activity for basic research and drug discovery,” according to Dr. James Strickler, Vice President of Research and Development at LifeSensors.

Ubiquitination, a post-translational modification, has been shown to play important roles in almost every aspect of physiology including cell growth and differentiation, inflammation, apoptosis, DNA repair, muscle and neuronal degeneration, and viral infection. Consequently, the imbalances between ubiquitination and deubiquitination of protein targets has been linked to several diseases in each of these areas. Ubiquitination is carried out by enzymes called ubiquitin ligases, while deubiquitination occurs by the highly specific activity of DUBs, which recognize both ubiquitin and the isopeptide bond. The inhibition or activation of DUBs is increasingly being explored for new drug development thereby creating a growing need for sensitive, reproducible substrates that can measure true isopeptidase activity as well as be supplied in quantities that can be used in high throughput formats.

LifeSensors, Inc. (lifesensors.com) is a biotech company established in 1996 and specializes in the development of tools and reagents for studying pathways involving ubiquitin and ubiquitin-like proteins. Currently, LifeSensors offers these novel IQF-substrates in both lysine-48- and lysine-63-linked diubiquitin forms with other polyubiquitin linkage types in development.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: LifeSensors, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


LifeSensors Awarded U.S. Patent for Novel Ubiquitin Pathway Enzyme Substrates

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Mark Engleka - LifeSensors.com 
610-644-8845 info[.]lifesensors.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any LifeSensors, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From LifeSensors, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Intrinsic Executive Search Ltd

Visit  S&A Capital Partner Ltd

Visit  RightITnow Ltd







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today